Clinical Observation On The Efficacy Of Erxianqiyi Prescription In Treating Cancer-related Fatigue, Qi Deficiency, Phlegm And Blood Stasis In Elderly Patients With Non-small Cell Lung Cance

Objective: To observe the clinical efficacy and safety of Erxian Qiyi Formula in the treatment of elderly patients with non-small cell lung cancer due to fatigue,qi deficiency,phlegm and blood stasis,and to provide guidance for clinical medication.Methods: A total of 70 patients were included,5 patients in each group were removed and eliminated,and 30 patients in each group were actually included in the control group and the treatment group.Both groups adopted the conventional anti-tumor basic scheme,the control group added Zi Long gold tablets to the basic treatment scheme,and the treatment group added Erxianqiyi recipe to the basic treatment scheme,with a course of 4 weeks.The scores of TCM symptoms,PFS scale,CFS scale,KPS scale,T lymphocyte subsets(CD3+,CD4+,CD8+)were compared before and after treatment.Results: 1.Before treatment,the general conditions(gender,age,pathological type,treatment mode)and various observation indexes(TCM symptom score,PFS scale,CFS scale,KPS scale)of the two groups had no statistical significance(P >0.05).2.Intra-group comparison: After treatment,the TCM symptom score,total score of PFS scale,all dimensions and total score of CFS scale and KPS score of the control group were statistically significant compared with those of the same group before treatment(P<0.05),but there was no significant difference in the fatigue degree of PFS before and after treatment(P > 0.05);The scores of the treatment group before and after treatment were statistically significant(P<0.05).3.Comparison between the two groups after treatment: there were significant differences in the total score of TCM symptoms,the effective rate of TCM,the fatigue degree and total score of PFS,and the dimensions and total score of CFS scale between the two groups(P<0.05),which indicated that the treatment group had better curative effect.The treatment group can better improve the symptoms of listlessness,fatigue,shortness of breath,lazy speech,shortness of breath and spontaneous sweating(P<0.05),and the KPS scores of the two groups are similar(P >0.05).4.Before treatment,Piper fatigue score was negatively correlated with CD3+ and CD4+ levels,while Piper fatigue score was positively correlated with CD8+ levels(P<0.05).After treatment,the immune indexes(CD3+,CD4+)negatively related to fatigue score were increased,and the immune indexes(CD8+)positively related to fatigue score were decreased in both groups(P<0.05).5.Before and after treatment,the general vital signs of the two groups were in good condition,and there was no significant difference in safety indicators.This drug is safe in treating cancer-related fatigue of elderly patients with non-small cell lung cancer.Conclusion: 1.Erxianqiyi recipe can effectively relieve the clinical symptoms of elderly patients with non-small cell lung cancer due to fatigue,qi deficiency and phlegm stasis,and improve the scores of PFS,CFS,KPS and immune indexes CD3+,CD4+ and CD8+.2.There is no adverse reaction in this study,that is,Erxianqiyi Formula is safe in the clinical treatment of cancer-related fatigue in elderly patients with non-small cell lung cancer.